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Abstract
Background: Organ dysfunction consequent to infection (‘severe sepsis’) is the leading cause of admission
to an intensive care unit (ICU). In both animal models and early clinical studies the calcium channel sensitizer
levosimendan has been demonstrated to have potentially beneficial effects on organ function. The aims of the
Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis (LeoPARDS) trial are to identify whether a
24-hour infusion of levosimendan will improve organ dysfunction in adults who have septic shock and to establish
the safety profile of levosimendan in this group of patients.
Methods/Design: This is a multicenter, randomized, double-blind, parallel group, placebo-controlled trial. Adults
fulfilling the criteria for systemic inflammatory response syndrome due to infection, and requiring vasopressor
therapy, will be eligible for inclusion in the trial. Within 24 hours of meeting these inclusion criteria, patients will be
randomized in a 1:1 ratio stratified by the ICU to receive either levosimendan (0.05 to 0.2 μg.kg-1.min-1 or placebo
for 24 hours in addition to standard care. The primary outcome measure is the mean Sequential Organ Failure
Assessment (SOFA) score while in the ICU. Secondary outcomes include: central venous oxygen saturations and
cardiac output; incidence and severity of renal failure using the Acute Kidney Injury Network criteria; duration of
renal replacement therapy; serum bilirubin; time to liberation from mechanical ventilation; 28-day, hospital, 3 and
6 month survival; ICU and hospital length-of-stay; and days free from catecholamine therapy. Blood and urine
samples will be collected on the day of inclusion, at 24 hours, and on days 4 and 6 post-inclusion for investigation
of the mechanisms by which levosimendan might improve organ function. Eighty patients will have additional
blood samples taken to measure levels of levosimendan and its active metabolites OR-1896 and OR-1855. A total
of 516 patients will be recruited from approximately 25 ICUs in the United Kingdom.
Discussion: This trial will test the efficacy of levosimendan to reduce acute organ dysfunction in adult patients
who have septic shock and evaluate its biological mechanisms of action.
Trial registration: Current controlled trials ISRCTN12776039 (19 September 2013)
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Background
Severe sepsis is defined as organ dysfunction consequent
to the systemic inflammatory response syndrome trig-
gered by infection. It is responsible for approximately
30% of all admissions to an intensive care unit (ICU) in
the United Kingdom (UK) yet, despite improvements in
care, the mortality from severe sepsis remains high. Ac-
cording to data from the UK Intensive Care National
Audit and Research Centre, the incidence of severe sep-
sis has increased by 68% over a nine-year period, such
that the total number of severe sepsis cases in the UK is
in excess of 45,000 per annum with a hospital mortality
rate of approximately 45% [1]. Mortality rates increase
with an increasing number of organ failures [2,3] whilst
the development of acute kidney injury (AKI) doubles
the risk of death [4].
Levosimendan
Levosimendan (Simdax™; Orion Corporation, Espoo, Finland)
is a licensed treatment for decompensated heart failure in
48 countries. It sensitizes the myocardium to calcium so
that a greater ventricular contraction (and thus stroke vol-
ume) can be achieved for the same intracellular calcium
concentration. In contrast to catecholamines, levosimen-
dan enhances cardiac performance without significantly
increasing myocardial oxygen demand [5]. The drug itself
has a short plasma half-life of approximately 1 hour, is ap-
proximately 95% bound to plasma proteins and is fully
metabolized in the liver and intestine into both active and
inactive metabolites. However, the hemodynamic effects
are maintained for up to 7 days after a single 24-hour infu-
sion of levosimendan due to the effects of the active me-
tabolite, OR-1896, which has an elimination half-life of
approximately 80 hours [6]. Levosimendan also causes
vasodilatation, mediated by activation of ATP-sensitive
vascular K+-channels [7], possesses anti-inflammatory
properties [8,9], and has been extensively investigated in
patients with acute heart failure due to a variety of etiolo-
gies [10].
Myocardial dysfunction is seen in over 50% of patients
with severe sepsis [11] and its presence is linked to
worse outcomes [12]. Implicated mechanisms include al-
tered calcium trafficking and reduced troponin sensitiv-
ity to calcium [13]. The calcium and anti-inflammatory
actions of levosimendan provide a strong biological ra-
tionale for its use in sepsis. In addition, conventional
vasoactive support using catecholamines such as nor-
epinephrine and dobutamine may result in sympathetic
nervous system overstimulation and a range of adverse
effects [14]. Evidence of a lack of benefit from trials com-
paring different catecholamine regimens [15], increased
mortality in patients exposed to a greater vasopressor load
[16], the observation of higher plasma catecholamine
levels in non-survivors compared to survivors of critical
illness [17], and emerging evidence that beta-blockade
may play a role if patients are receiving high-dose cate-
cholamines [18] all provide further evidence of possible
harm from conventional catecholamine therapy.
Beneficial effects from the use of levosimendan in se-
vere sepsis have been reported in animal models [19-23].
In humans, several case reports, case series [24-27] and
small single-centre clinical trials [28-33] provide good
evidence to support the hypothesis that levosimendan
may be a promising therapy in severe sepsis. Morelli
et al. conducted a randomized controlled trial compar-
ing an infusion of levosimendan at 0.2 ug.kg−1.min−1 to
dobutamine at 5 μg.kg−1.min−1 for 24 hours in 28
patients with septic shock and echocardiographically
proven acute left ventricular dysfunction [28]. As well as
improving hemodynamics, levosimendan increased cre-
atinine clearance by 64% compared to dobutamine at
5 μg.kg−1.min−1. In a randomized placebo-controlled
trial in 35 patients with septic shock and the acute re-
spiratory distress syndrome, levosimendan at 0.2 μg.kg−1.
min−1 increased cardiac index and reduced mean pul-
monary artery pressure compared to placebo [29]. In a
further randomized controlled study in 40 patients with
septic shock, levosimendan at 0.2 μg.kg−1.min−1 signifi-
cantly improved microcirculatory flow when compared
to dobutamine at 5 μg.kg−1.min−1 [30]. Two similar
studies in septic shock (both randomized controlled
trials) demonstrated improved hemodynamics with re-
duced requirements for additional catecholamines [31]
and improvements in cardiac output and mixed venous
oxygen saturation [32] with the use of levosimendan.
Another trial of 30 patients showed improved hepatic
function, measured by indocyanine green clearance, with
levosimendan compared to dobutamine at 5 μg.kg−1.min−1
[33]. Further evidence to support an improvement in
organ function comes from a retrospective analysis of 99
patients with septic shock who received levosimendan at
0.2 μg.kg−1.min−1 for 24 hours within 36 hours of admis-
sion to the ICU [34]. When compared to matched con-
trols, levosimendan-treated patients demonstrated a 24%
increase in glomerular filtration rate at 96 hours together
with a reduced peak serum creatinine.
Risks
Levosimendan has been widely used in patients with
acute heart failure with a good safety profile and no
known significant pharmacokinetic drug interactions.
According to the levosimendan investigators’ brochure,
between September 2000 (when the drug first received a
license in Sweden) and November 2010 an estimated
440,000 patients have received the drug with a reported
serious adverse drug reaction rate of 791 out of 440,000
(0.2%). The most common adverse events reported were
hypotension (0.03%) and serious arrhythmias (0.02%).
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Levosimendan has also been used in over 200 patients
with septic shock in published controlled trials and case
series without any reported significant adverse effects.
Adequate cardiovascular resuscitation with intravenous
fluids and norepinephrine, as well as avoiding both
the initial bolus loading dose and a high-dose infusion
(≥0.4 μg.kg−1.min−1) help reduce adverse effects when
used in sepsis [35]. Levosimendan is currently used in
many ICUs within Europe in the treatment of severe
sepsis and septic shock and has recently been recom-
mended as an alternative inotrope in the German Sepsis
Society guidelines [36].
There is therefore good evidence that levosimendan
improves cardiac output, regional perfusion, and other
physiological endpoints, including renal function, in pa-
tients with septic shock. This trial is therefore designed
to identify important clinical outcome benefits and to
further explore the mechanisms of action of levosimen-
dan in septic shock.
Methods/Design
The Levosimendan for the Prevention of Acute oRgan
Dysfunction in Sepsis (LeoPARDS) trial is a multicenter
prospective, randomized, double-blind, parallel group,
placebo-controlled trial. The trial is sponsored by Imper-
ial College London (United Kingdom) and coordinated
by the Imperial Clinical Trials Unit. The trial will be
conducted in accordance with the principles of the
Declaration of Helsinki and Good Clinical Practice and
is approved by the independent National Research Ethics
Committee London - Harrow (13/LO/0365). It is regis-
tered on the European Union Drug Regulating Author-
ities Clinical Trials database (EudraCT 2012-005159-18)
and the International Standardised Randomised Con-
trolled Trial Registry (ISRCTN12776039). The study
is funded by the Efficacy and Mechanism Evaluation
(EME) program of the National Institute for Health Re-
search (United Kingdom)
The primary objectives of the trial are as follows: (1) to
ascertain if levosimendan reduces the incidence and sever-
ity of organ dysfunction compared to placebo in adult
patients who have septic shock; (2) to identify the effect
of levosimendan on individual organ function in septic
shock; and (3) to establish the safety profile and pharma-
cokinetics of levosimendan in this group of patients.
The secondary objectives of the study are: (1) to identify
whether levosimendan reduces the need for and duration
of catecholamine support and thus reduces myocardial in-
jury; (2) to establish whether levosimendan alters the pro-
and anti-inflammatory balance in sepsis; and (3) to collect
long-term (3 and 6 month) survival data to help inform
the appropriate long-term outcome measure for a subse-
quent effectiveness trial, should the efficacy of levosimen-
dan be confirmed in this phase IIb trial.
Inclusion criteria
The target population is adult patients (≥18 years) who
require vasopressor support for the management of sep-
sis despite fluid resuscitation. Patients being treated on
an ICU with suspected or confirmed infection will be
eligible for the trial if they meet both of the following
criteria:
Sepsis - fulfil two of the four criteria for the systemic in-
flammatory response syndrome (SIRS): (1) fever (>38°C)
or hypothermia (<36°C); (2) tachycardia (heart rate >90
beats per minute); (3) tachypnea (respiratory rate >20
breaths per minute or PaCO2 < 4.3 kPa) or need for mech-
anical ventilation; (4) abnormal leukocyte count (>12,000
cells/mm3, <4000 cells/mm3, or >10% immature band
forms).
Shock- hypotension, despite adequate fluid resuscita-
tion, requiring treatment with a vasopressor infusion
(such as norepinephrine, epinephrine, or vasopressin
analogue) for at least 4 hours and still having an ongoing
vasopressor requirement at the time of randomisation.
Exclusion criteria
The presence of any of the following criteria will prevent
entry into the study: more than 24 hours since meeting all
of the inclusion criteria; end-stage renal failure at presen-
tation (previously dialysis-dependent); severe chronic
hepatic impairment (Child-Pugh class C); a history of
Torsades de Pointes; known significant mechanical ob-
structions affecting ventricular filling or outflow or both;
treatment limitation decision in place (such as Do Not
Attempt Resuscitation or not for ventilation and/or dialy-
sis); known or estimated weight >135 kg; known to be
pregnant; previous treatment with levosimendan within
30 days; known hypersensitivity to levosimendan or any of
the excipients; known to have received another investiga-
tional medicinal product within 30 days or currently in
another interventional trial that might interact with the
study drug.
Primary outcome measure and sample size
This trial is designed to explore the efficacy and mech-
anism of action of levosimendan, as well as inform a
subsequent effectiveness trial if appropriate. We will
therefore examine organ dysfunction as measured by the
Sequential Organ Failure Assessment (SOFA) score [2] as
the primary endpoint (excluding the neurological compo-
nent). We will compare mean SOFA scores between treat-
ment groups. The mean SOFA in ICUs has been shown to
be closely correlated to mortality and its predictive value
was similar regardless of length of stay [3].
Our sample size of 500 patients will provide more than
90% power to detect a 0.5 point difference in the mean
SOFA score assuming a SD of 1.5 [3]. In this previous
validation study a 1 point rise in the mean SOFA score
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was associated with a significant mortality increase
(mean SOFA 2.1 to 3.0 = 20%, 3.1 to 4.0 = 36.1% and 4.1
to 5.0 = 73.1% mortality; odds ratio 3.06, 95% CI 2.36 to
3.97). We will recruit an additional 3% (16 patients) to
account for potential loss to follow-up and withdrawal
of consent, as seen in previous UK ICU trials [37], giving
a total of 516 patients with 258 in each arm (Figure 1).
Secondary outcome measures
The SOFA score is a composite of several different organ
failures and there may be differential effects of levosimen-
dan in different organ systems. Therefore, in order to gain
further insight into the mode of action of levosimendan
we will also measure organ specific outcomes.
Cardiovascular
We will compare oxygen delivery between treatment
groups using central venous oxygen saturations (ScvO2).
This will be measured and recorded at baseline, 6, and
12 hours, and then 12-hourly in all patients with an
internal jugular or subclavian central venous catheter
(CVC) for up to 96 hours, if the CVC remains in situ.
The study will have more than 95% power to detect a
5% difference in ScvO2 assuming a SD of 15%.
Cardiac output monitoring using specified devices
(PiCCO™, LiDCOplus™, esophageal Doppler, or pulmon-
ary artery catheter) will be measured in select centers, at
baseline, 6, 12, and 24 hours, and then 12-hourly for up
to 96 hours or as long as the device is clinically required
Figure 1 LeoPARDS proposed trial flow diagram. CCMDS, Critical Care Minimum Data Set; ICU, Intensive Care Unit; SOFA, Serial Organ
Failure Assessment.
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if shorter. Based on cardiac output data from the Vaso-
pressin and Septic Shock Trial (VASST), a subgroup of
150 patients will provide more than 85% power to detect
a 0.66 l.min−1.m−2 difference in cardiac index between
treatment groups over this period assuming an SD of 1.3
[38]. We will also examine the effect of levosimendan in
the subgroup of patients who have a low cardiac output
at baseline, as evidenced by a low ScvO2 or measured
cardiac output.
Respiratory
Recent evidence has suggested levosimendan may also
enhance calcium sensitivity in the diaphragm muscle
and thus improve diaphragm contractility [39]. In those
patients who require intubation and mechanical ventila-
tion we will assess time to successful liberation from
mechanical ventilation. This will be defined as: (1) extu-
bated with face mask, nasal cannulae or room air, or (2)
T-piece/heat and moisture exchange (HME) filter breath-
ing, or (3) tracheostomy mask breathing, or (4) CPAP
breathing ≤5 cm H2O without any pressure support or
mandatory ventilation.
A total of 450 patients (90% of the sample size of 500)
will provide 80% power to detect a hazard ratio of 1.4,
based on the assumption that 63% of patients will be suc-
cessfully liberated from mechanical ventilation by day 28.
Renal
In view of the data demonstrating a beneficial effect of
levosimendan on renal function in sepsis we will com-
pare stages (0, 1, 2, and 3) of AKI using the Acute Kid-
ney Injury Network (AKIN) definition [40]. Since death
is clearly a worse outcome than renal failure, patients
who have died will be categorized into a fifth stage.
These five groups at day 14 will be analyzed as ordinal
categorical data, using a constrained non-proportional
odds model such that the log-odds ratios are assumed
constant across all the cumulative probabilities except
the last (death).
Power calculations have been undertaken using simu-
lation with multi-state modeling based on previous data
from previous septic shock trials [41-43]. These simula-
tions suggested that the maximum difference in rates of
AKI and death between treatment groups might be seen
around day 14. The trial will have between 65 and 90%
power to detect between 25 and 35% improvement in
renal function with levosimendan.
Secondary mechanistic outcomes
Serial blood and urine samples will be collected from pa-
tients at baseline, day 2, 4 and 6. Assays will include
markers of AKI, myocardial dysfunction, inflammation,
and intestinal perfusion. Possible assays are given below
but as biomarker discovery is a very active area of
research we will re-evaluate the best assays available at
the time that study enrolment is complete and consider
the use of additional or complementary biomarkers.
Current possible assays include (1) AKI biomarkers
in urine and plasma. Urinary Neutrophil Gelatinase-
Associated Lipocalin (NGAL) is currently the best vali-
dated biomarker of AKI [44]. Alternative biomarkers of
AKI (such as Kidney Injury Molecule-1 or cell cycle
arrest biomarkers [45]) may be better characterised
and validated by the end of the trial. (2) Markers of
myocardial dysfunction. Serum B-type Natriuretic Pep-
tide (BNP) has been demonstrated to be a reliable bio-
marker of myocardial injury, ischemia, and dysfunction
in septic patients and also as a prognostic marker for
a poor outcome [12,46]. (3) Biomarkers of systemic
inflammation. This will be measured using a multiplex
inflammatory biomarker assay. This will allow an assess-
ment of the pro- and anti-inflammatory cytokine balance
over time in patients with septic shock and allow a more
detailed study of the other potential mechanisms of ac-
tion of levosimendan. In addition, samples will be stored
for subsequent analysis as appropriate.
Pharmacokinetic substudy
The initial 80 patients enrolled in the study will have an
additional 3 ml of blood collected while on ICU on days
2, 4, 6, 8, 10, 13 and 16 for assays of levosimendan and
its active metabolite OR-1896. We will then compare
the area under the curve (AUC) and the maximum con-
centration (Cmax) between patients with and without
AKI and also with previous pharmacokinetic data from
other studies. The drug and metabolite levels will be
correlated to possible adverse hemodynamic events,
namely tachycardia and hypotension. The independent
Data Monitoring and Ethical Committee (DMEC) will
be asked to suggest alternative dosing regimens if drug
or metabolite levels are unexpectedly high in certain pa-
tient groups or if there is an association between infu-
sion rates, drug levels, and adverse events. They will
advise if any alternative dosing regimens should alter the
sample size for the trial.
Trial conduct
Consent
All patients in ICU who are clinically judged to have se-
vere sepsis will be screened against the inclusion and ex-
clusion criteria. Informed consent will be obtained prior
to enrolling patients into the trial. In most cases it will
not be possible to obtain prospective consent from the
patient due to a lack of capacity as a result of their crit-
ical illness and its treatment. Under such conditions,
written informed consent will be sought from the pa-
tient’s personal legal representative (PerLR) who will be
provided with a copy of the Patient Information Sheet
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(PIS). If the patient lacks capacity and there is no PerLR
then a doctor, unconnected with the trial, may act as a
professional legal representative (ProLR) and provide
consent for enrolment into the trial. All surviving pa-
tients will be informed about the trial once they regain
capacity and will be asked to give consent to their on-
going involvement in the trial.
Randomization and supply of study drug
Orion Corporation (Espoo, Finland) is providing the
study drugs for the trial. Levosimendan 12.5 mg/5 mls
vials and identical placebo will be supplied to Victoria
Pharmaceuticals (Belfast, UK) who will be responsible
for packaging, labelling, and distributing the drugs to
study sites in accordance with Medicines and Healthcare
products Regulatory Agency (MHRA) requirements.
Randomization will be by computer generated random-
ized numbers and will use an online system (InForm™,
Oracle Corp, California, United States). Randomization
will be stratified by ICU and will occur on a 1:1 basis in
permuted blocks.
Administration of study drug
Patients will be randomized to receive an intravenous in-
fusion of levosimendan at 0.05 to 0.20 μg.kg−1.min−1 or
placebo for a period of 24 hours. The infusion will be
prepared by diluting the contents of one vial of study
drug in 500 ml of 5% dextrose. The study drug will not
be started until the treating clinician is confident that
adequate fluid resuscitation has been achieved and that
the patient has reached their target blood pressure;
this may be a mean arterial pressure (MAP) of 65 to
70 mmHg but may be increased or reduced if the treat-
ing clinician feels this is clinically necessary. The infu-
sion will then be commenced at a rate of 0.1 μg.kg−1.
min−1 based on actual (estimated) body weight. Al-
though the summary of product characteristics states
that an initial bolus of levosimendan should be given, in
this trial the bolus dose will not be given to avoid
hypotension and maintain patient safety. After 2 to 4 hours
the infusion will be increased to 0.2 μg.kg−1.min−1 for the
remaining 20 to 22 hours if there is no significant
hypotension or tachycardia. Any initial hypotension will
be treated with a fluid challenge and an increase in vaso-
pressor dose if needed. Throughout the duration of the in-
fusion, clinicians will have the option to reduce the
infusion or stop it if they deem there to be significant
hypotension or tachycardia. Details of the study drug infu-
sion protocol are shown in Figure 2. Titration of the study
drug dose between 0.05 and 0.2 μg.kg−1.min−1 will ensure
patients receive an effective dose whilst minimizing ad-
verse effects.
General patient management and treatment
Patients will receive all normal standard care and be
managed in accordance with current accepted best prac-
tice as recommended by the Surviving Sepsis Campaign
(SSC) guidelines [47]. Crystalloid solutions will be used
for intravenous fluid resuscitation. Gelatin-based or
human albumin solutions may be used as alternative re-
suscitation solutions. Norepinephrine is the initial vaso-
pressor of choice. This should be titrated to a target
MAP of 65 to 70 mmHg or as deemed appropriate by
the treating clinician. Vasopressin, or any of its ana-
logues, may be used as an alternative vasopressor or in
addition to norepinephrine. The lowest dose of vaso-
pressor that maintains a MAP that provides acceptable
tissue perfusion should be used. Additional inotropic
drugs may be used as clinically indicated. Dobutamine is
the inotropic agent of choice but others, such as epi-
nephrine or milrinone, may be used. A central venous
saturation (ScvO2) of more than or equal to 70% should
be targeted in the early stages of septic shock manage-
ment. Dobutamine (or any other inotropes) should be ti-
trated down and weaned off once an adequate oxygen
delivery is achieved. Hydrocortisone should only be used
for patients who are poorly responsive to vasopressors,
as per the SSC guidelines [47]. Low doses, such as
200 mg hydrocortisone administered intravenously daily
in divided doses or by infusion, should be used and
weaned off once shock resolves.
A lung-protective strategy should be used: target tidal
volume 6-ml.kg−1 ideal body weight, limiting plateau pres-
sure to ≤30 cmH2O, accepting permissive hypercarbia,
and ensuring adequate levels of positive end-expiratory
pressure (PEEP). High frequency oscillation, neuromuscu-
lar blockade, inhaled nitric oxide, prone positioning, and
extra-corporeal membrane oxygenation are all permitted
as needed for the management of refractory hypoxemia.
Continuous veno-venous hemo(dia)filtration is the renal
replacement therapy of choice, however, other modalities
such as intermittent hemodialysis may be used since there
is no clear evidence that one modality is superior [48].
High volume hemofiltration solely for the treatment of
sepsis in the absence of renal failure should not be used.
Pharmacovigilance & patient follow-up
An assessment of the safety of levosimendan is an im-
portant outcome measure for the LeoPARDS trial. Given
that the trial is being conducted in critically ill patients,
a significant number of patients are likely to experience
adverse events (AEs). Events that are in keeping with the
patient’s clinical condition will not be reported as AEs.
The following clinical outcomes from sepsis will not be
recorded as AEs unless the local investigator deems the
event to be related to the study drug or the protocol:
death, cardiovascular failure, respiratory failure, hepatic
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failure, renal failure, and hematological failure. Specific in-
formation about the occurrence of a myocardial infarction
or acute coronary syndrome and life-threatening arrhyth-
mias will be recorded in the case report form. All adverse
events will be assessed for likely relationship to the study
drug. All serious adverse event (SAE) or a suspected unex-
pected serious adverse reaction (SUSAR) will be reported
to the trial coordination centre within 24 hours and to the
relevant authorities in accordance with current regulations.
Patients will be followed up on daily whilst on the ICU.
Routinely collected clinical data (cardiovascular, respiratory,
and renal physiological variables as well as hematological
and biochemical blood test results) will be recorded on a
daily basis during this time using the electronic case report
form. Patients will also be followed up to ascertain survival
status at 28 days post-recruitment, at hospital discharge,
and at 3 and 6 months post-recruitment using The Health
and Social Care Information Centre.
Statistical analysis and trial oversight
A full statistical analysis plan will be drawn up be-
fore the trial database is locked and analyzed. Prior
to performing any statistical tests or fitting statistical
models, an exploratory analysis of the baseline vari-
ables and outcome measures will be completed. The
level and pattern of missing data in the baseline vari-
ables and outcomes will be established by forming
appropriate tables and likely causes of any missing
values will be investigated. Any issues will be dealt
with using standard statistical techniques. The pri-
mary analyses will be carried out on an intention-to-
treat basis. The Trial Steering Committee (TSC) with
an independent chair and a majority of independent
members including patient and public representatives
will be responsible for overseeing the progress of the
trial and will meet six-monthly. The independent
DMEC will meet six-monthly to review ongoing
recruitment, protocol compliance, clinical outcome,
and adverse event data. They will provide the TSC
with written reports advising about ongoing trial
conduct.
The trial will end once 516 patients have been en-
rolled, all patients have completed 6 months follow-up
and the database is locked.
Figure 2 LeoPARDS blinded study drug infusion management guideline. HR, Heart rate; MAP, Mean Arterial Pressure. ⬆ = increased.
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Discussion
There is good evidence from pre-clinical studies [19-23],
case series [24-27], and small clinical trials [28-33] look-
ing at physiological endpoints that levosimendan may
have a beneficial role in the management of septic shock.
Its mechanism of action as a calcium sensitizer means it
has theoretical advantages over other inotropic drugs,
including less increase in myocardial oxygen demand
and reduced rates of arrhythmias. It may also improve
peripheral organ perfusion and have anti-inflammatory
properties.
This trial will test the clinical efficacy of levosimendan
to reduce acute organ dysfunction in adult septic shock
and will also examine its safety profile in this patient
group. The primary outcome measure (mean SOFA
score) allows an overall assessment of the effect of the
drug on organ function which is known to correlate with
survival. However, as a composite score it is vital to
examine each organ system separately to fully under-
stand the biological effect of levosimendan. The collec-
tion and analysis of blood and urine samples will also
allow a fuller examination of its biological effects.
Trial status
The trial is due to open for recruitment in January 2014. Re-
cruitment of all 516 patients is expected to take 30 months.
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